Keyphrases
Placebo
100%
Preterm Labor
100%
Randomized Trial
100%
Atosiban
100%
Retosiban
100%
Time to Delivery
30%
Placebo-controlled Trial
30%
Treatment Failure
20%
Gestational Age
20%
Neonate
10%
Obstetrics
10%
Pharmaceutical Companies
10%
Adverse Events
10%
Intact Membrane
10%
Adjusted Means
10%
Diagnostic Criteria
10%
Singleton Pregnancy
10%
Time-to-treatment
10%
Double-blind Trial
10%
Placebo Groups
10%
Composite Neonatal Morbidity
10%
Regulatory Agencies
10%
Composite Endpoint
10%
Ethics Committees
10%
Participant Characteristics
10%
March 2015
10%
Co-primary Endpoints
10%
Committee Decisions
10%
Delivery Failure
10%
Medicine and Dentistry
Placebo
100%
Premature Labor
100%
Atosiban
100%
Retosiban
100%
Gestational Age
20%
Adverse Event
10%
Neonate
10%
Obstetrics
10%
Cooperation
10%
Diagnostic Criterion
10%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Premature Labor
100%
Atosiban
100%
Retosiban
100%
Adverse Event
10%
Agricultural and Biological Sciences
Placebo
100%
Atosiban
100%
Endpoints
30%
Gestational Age
20%
Committees
10%
Neonate
10%
Ethics
10%